Core Viewpoint - The article discusses the controversy surrounding Kangfang Biopharma, particularly regarding the distribution of clinical trial drugs to patients, while also highlighting the company's recent achievements in drug approvals and its financial challenges. Group 1: Controversy and Response - Kangfang Biopharma is facing scrutiny after a patient reported purchasing a significant amount of the drug Cadonilimab, only to find that most of the drugs received were clinical trial medications not approved for market sale [3][4][14]. - The company has denied any wrongdoing, asserting that it has never charged patients for clinical trial drugs and that the sales personnel involved acted independently [12][13]. - A significant internal investigation was launched by the company to address the allegations, revealing that some sales personnel had forged documents to obtain clinical trial drugs [14][15]. Group 2: Drug Approvals and Clinical Value - Cadonilimab has received multiple approvals, including a recent one for first-line treatment of cervical cancer, marking a significant advancement in immunotherapy for this indication [4][17]. - The drug has been involved in over 30 clinical studies targeting various cancers, demonstrating its clinical value and potential for broader application [18]. - Kangfang Biopharma's other key product, Ivoris, has also made headlines for its innovative dual-target mechanism and successful clinical trials against leading competitors [21][22]. Group 3: Financial Performance and Commercialization - The company has incurred significant losses, with total losses exceeding 2 billion yuan, primarily due to high R&D expenditures and commercialization efforts [34][41]. - From 2017 to 2024, Kangfang Biopharma's R&D spending reached 6.2 billion yuan, with 2024 alone accounting for 1.187 billion yuan, representing 55% of total revenue [36]. - Despite the financial challenges, the company has raised approximately 7.9 billion HKD through multiple rounds of equity financing, providing a cash reserve to support ongoing projects [42][43].